Mirvie
Mirvie uses RNA technology to predict pregnancy complications like preeclampsia and preterm birth months in advance.
Through a simple blood test, it enables personalized, preventive care based on each pregnancy’s unique biology.
Mirvie's 2025 study, published in Nature Communications, demonstrates that their RNA-based blood test can predict 91% of preterm preeclampsia cases months before symptoms appear.
The research, involving over 9,000 pregnancies, identified distinct molecular subtypes of preeclampsia, enabling more personalized prenatal care.
Notably, the test achieved an area under the curve (AUC) of 0.88 in predicting preterm preeclampsia among women aged 35 and older without existing high-risk conditions. Additionally, a low-risk result correlated with a 99.7% probability of not developing the condition.
This study underscores the potential of RNA profiling to enhance early detection and individualized management of pregnancy complications.
Learn more about this study and others here.
Research